Market revenue in 2023 | USD 2,983.8 million |
Market revenue in 2030 | USD 5,967.4 million |
Growth rate | 10.4% (CAGR from 2023 to 2030) |
Largest segment | Hba1c tests |
Fastest growing segment | HGB/HCT tests |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Complete blood count, HGB/HCT tests, Basic metabolic panel, BUN creatinine tests, Electrolytes testing, HbA1c tests, Comprehensive metabolic panel tests, Liver panel tests, Renal panel tests, Lipid panel tests |
Key market players worldwide | Quest Diagnostics Inc, Abbott Laboratories, Labcorp Holdings Inc, ARUP Laboratories, OPKO Health Inc, Clinical Reference Laboratory, Sonic Healthcare Ltd, Cinven, Unilabs |
Hba1c tests was the largest segment with a revenue share of 12.53% in 2023. Horizon Databook has segmented the UK clinical laboratory tests market based on complete blood count, hgb/hct tests, basic metabolic panel, bun creatinine tests, electrolytes testing, hba1c tests, comprehensive metabolic panel tests, liver panel tests, renal panel tests, lipid panel tests covering the revenue growth of each sub-segment from 2018 to 2030.
The clinical laboratory tests market in the UK is expected to witness rapid growth over the forecast period due to increasing prevalence of chronic diseases, growing awareness about early diagnosis, and improvements in healthcare infrastructure. Using clinical data informatics platforms through productive research collaborations is anticipated to propel the market growth over the forecast period.
The UK NHS provides free universal coverage for clinical testing to all citizens. Most of the tests are provided for by NHS laboratories; however, private laboratories have recently entered the market, making an impact by increasing revenue and the number of tests offered.
In addition, developing novel products to diagnose chronic disorders is another major factor driving the market. For instance, in July 2022, Metadeq, Inc., a startup based in London, announced a revolutionary non-invasive blood test that utilizes two new circulating proteins to precisely diagnose liver fibrosis and NASH and determine the stages of both diseases without the need for a liver biopsy.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account